We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Keith
Boland
+44 20 7594 9480
refine-lung@imperial.ac.uk
Dr
Michael
Seckl
+44 20 3311 1421
m.seckl@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Lung cancer
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Background and study aims
Lung cancer is the most common cause of cancer death. Things have improved with the use of drugs like pembrolizumab, which is often used following a diagnosis of advanced non-small cell lung cancer (NSCLC). Pembrolizumab uses the immune system, the body’s natural defence. The immune system sends cells called T cells to fight infections and diseases. Cancer cells hide in the ‘PD-1/PD-L1 pathway’, allowing them to grow and spread. Pembrolizumab blocks the pathway. This prevents cancer cells from hiding, meaning they can be killed by T cells. The cancer may shrink or disappear as a result.
Treatment is usually every 6 weeks, sometimes with chemotherapy. Treatment can last 2 years, and this may be too much. Research has not shown that length increases benefit, and many people who stop before 2 years continue to benefit from pembrolizumab after it has finished.
There is a possibility that researchers can reduce treatment frequency without effectiveness being reduced. This is the main aim of REFINE-Lung.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Disease progression or not tolerating treatment at 6 months into therapy 2. Clinician does not intend to continue immunotherapy3. Is currently receiving an investigational agent or has participated in a study of an investigational agent and or used an investigational device within 28 days of randomisation
Added 04/07/2023:4. Any patient with a synchronous primary cancer. This includes any new cancer diagnoses or relapse of previously treated cancer since starting pembrolizumab treatment.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Keith
Boland
+44 20 7594 9480
refine-lung@imperial.ac.uk
Dr
Michael
Seckl
+44 20 3311 1421
m.seckl@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Imperial College London and funded by Health Technology Assessment Programme.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 52203
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
